Showing 8851-8860 of 21421 results for "".
IgAN SOC: Strengths and Limits
https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.APRIL Uncovered: An Upstream Driver in IgAN
https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Evidence: IgAN Disease-Modifying Agents
https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Therapies in IgAN: Who Could Benefit the Most?
https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Women in Aesthetics: Isabelle Raymond, PhD
https://reachmd.com/ma-issues-index/september-october-2025/women-in-aesthetics-isabelle-raymond-phd/39727/Get to know Isabelle Raymond, PhD, SVP Global Medical and Clinical Affairs with Nutrafol